Omeros Beats Q3 Estimates as YARTEMLEA Sales Rise
Omeros reported third-quarter 2026 earnings of $0.06 per share, beating the consensus estimate of a loss of $0.05 per share and improving on a loss of $0.19 per share a year earlier. Sales of its transplant complication treatment YARTEMLEA rose year over year.